Cost-effectiveness of whole-exome sequencing in progressive neurological disorders of children

Abstract

WES is an efficient and cost-effective diagnostic tool that should be prioritized in early diagnostic path of children with progressive neurological disorders. The progressively decreasing price of the test improves cost-effectiveness further.